The prostate cancer in departments of Isere and Tarn (France) between 1985 and 1995: Evolution of therapeutics;Le cancer de la prostate dans les departements de l'Isere et du Tarn entre 1985 et 1995: Evolution des indications therapeutiques

Bulletin du Cancer

Volumn 85, Issue 12, 1998, Pages 1049-1054

  Chirpaz, Emmanuel ^a   Ménégoz, François ^a   Grosclaude, Pascale ^c   Colonna, Marc ^a   Bénard, Éric ^c   Rambeaud, Jean Jacques ^b  

^a Registre du Cancer de l'Isere   (France)

^b HÔPITAL MICHALLON   (France)

^c NONE

Author keywords

Prostate cancer; Therapeutic indications; Therapeutic practices

Indexed keywords

HORMONE;

ARTICLE; CANCER RADIOTHERAPY; EVOLUTION; FRANCE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY;

ADENOCARCINOMA; AGE FACTORS; AGED; FRANCE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PHYSICIAN'S PRACTICE PATTERNS; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; REGISTRIES; RETROSPECTIVE STUDIES;

EID: 0032417468     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. 1. Lu Yao GL. Changes in prostate cancer incidence and treatment in USA. Lancet 1994 ; 343 : 251-4.
2. 2. Hill C, Benhamou H, Doyon F, Flaman R. Évolution de la mortalité par cancer en France 1950-1985. Inserm, 1989, Paris.
3. 3. Menegoz F, Black RJ, Arveux P, et al. Cancer incidence and mortality in France 1975-1995. Eur J Cancer Prev 1997 ; 6 : 442-66.
4. 4. Menegoz F, Colonna M, Exbrayat C, Mousseau M, Orfeuvre H, Schaerer R. A recent increase in the incidence of prostatic carcinoma in French population : role of ultrasonography and prostatic specific antigen. Eur J Cancer 1995; 31A : 55-8.
5. 5. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection organconfined prostate cancer is increased through prostat specific antigenbased screening. JAMA 1993 ; 270 : 948-54.
6. 6. Nomura AMY, Kolonel LN. Prostate cancer : a current perspective. Am J Epidemiol 1991 ; 13 : 200-21.
7. 7. Shrader-Bogen CL, Kkjellberg JL, Mac Pherson CP, Murray CL. Quality of life and treatment outcomes. Cancer 1997 ; 7: 1977-85.
8. 8. Bolla M, Rambeaud JJ, Vincent F. Local prostatic carcinoma. Ed. Karger, 1994.
9. 9. Cancer de la prostate. Monogr Rev Prat 1994 ; 5 : 573-622.
10. 10. Lerner SP, Seale-Hawkins C, Carlton CE, Scardino PT. The risk of dying of prostate cancer in patients with clinically localised disease. J Urol 1991 ; 146: 1040-5.
11. 11. Cooner WH, Mosley BR, Rutherford CL, et al. Prostate cancer detection in clinical urological practice by ultrasonography, digital rectal examination and PSA. J Urol 1989 ; 143 : 1146-54.
12. 12. Oesterling JE. A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991 ; 145 : 907-23.
13. 13. Zagars GK, Pollack A, von Eschenbach AC. Prognostic factors for clinically localized prostate carcinoma. Cancer 1997 ; 79 : 1370-80.
14. 14. Franks L.M. Latent carcinoma of the prostate. J Path Bact 1994 : 603-16.
15. 15. Johanson JE, Adami HO, Andersen SO, Bergstrom R, Holmberg L, Krusemo UB. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 1992 ; 267 : 2191-6.
16. 16. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenom. N Engl J Med 1985; 312 : 1604-8.
17. 17. Whitmore WF. Management of clinically localised prostatic cancer. JAMA 1993 ; 269 : 2676-7.
18. 18. Walsh PC. Why made an early diagnosis of prostate cancer. J Urol 1992; 147: 853.
19. 19. Whitmore WF. Natural history of low-stage prostatic cancer and the impact of early detection. Urol Clin North Am 1990 ; 17 : 689-96.
20. 20. Post PN, Kil PJM, Crommelin MA, Schapers RFM, Cœbergh JWW. Trends in incidence and mortality rates for prostate cancer before and after prostate specific antigen introduction. A registry-based study in Southeastern Netherlands, 1971-1995. Eur J Cancer 1998; 34: 705-9.
21. 21. Coffey DS. Prostate cancer. Cancer 1993 ; 71 : 880-6.